CAR T-Cell Therapy gudaha Malaysia

MALAYSIAN Genomics Resource Center Bhd (MGRC) rajaynaynaa in ay sameeyaan ay chimeric antigen receptor (CAR) daawaynta unugyada T-cell daawaynta laga heli karo Malaysiya wax ka yar RM200,000 ie ku dhawaad ​​$45,000 USD, taas oo qayb ka ah kharashka daawaynta ee Yurub iyo Maraykanka. Waxaan rajeyneynaa in daaweynta CAR T-Cell ee Malaysiya ay farxad u keeni doonto kumanaan bukaan ah kuwaas oo rajeynaya inay helaan daaweyntan horumarsan.

Sawirka: CAR T daawaynta unug ayaa sidoo kale loo sameeyay noocyo ka mid ah burooyinka adag

Sida laga soo xigtay madaxa shirkadda Genomics ee Malaysian Sasha Nordin, shirkaddu waxay la kaashatay Shiinaha ICARTAB Biomedical Co Ltd, taas oo horumarinaysa tiknoolajiyada si gaar ah loogu talagalay cudurrada adag ee adag, inkastoo xaqiiqda ah in daawaynta la midka ah ee cudurada dareeraha ama dhiigga ay horayba uga heli jireen wadamada reer galbeedka.

"Hagaajinta gelitaanka alaabta cusub waa qayb ka mid ah waajibaadkeena." Waxaan awoodnay inaan gaarno heshiis noo ogolaanaya inaan u diyaarno bukaannada Koonfur-bari Aasiya qayb yar oo ka mid ah qiimaha.

Waraysi uu siiyay kaydka Malaysiya shalay, waxa uu yidhi, "Waxa aanu ka shaqaynaynaa sidii aanu ugu heli lahayn wax ka yar RM200,000 iyo US$400,000 (RM1.61 million) ugu yaraan Yurub iyo Maraykanka."

MGRC waxay noqon doontaa qaybiyaha rasmiga ah ee daaweynta CAR T-Cell ee Singapore, Brunei, Indonesia, Thailand, Vietnam, Cambodia, iyo Laos, marka lagu daro Malaysia.

Sida ay sheegtay Sasha Cumar, shirkaddu waxay hadda haysaa dawo lix ka mid ah tobanka cudur ee ugu sarreeya gobolka, oo ay ku jiraan beerka, ganaca, mesothelioma, hunguriga, maskaxda, iyo burooyinka caloosha. Wuxuu sheeganayaa in CAR T-cell immunotherapy Kansarka adag maahan daawayn la soo saaray.

Daawaynta kasta oo ku jirta daawaynta waa mid u gaar ah bukaanka maadaama ay ka mid tahay soo saarista unugyada bukaanka iyo u oggolaanshaha T-unugga bukaanka, unugga dhiigga cad ee muhiimka ah ee nidaamka difaaca, inuu aqoonsado burada.

Unugga T-ka ayaa markaa dib loogu celin doonaa jirka bukaanka si loo ogaado oo loola dagaallamo unugga malignantiga ah, isaga oo ka hortagaya inuu sii faafo.

"Mar kasta oo aan la kulanno bukaan, waa inaan maraa habraac u qalmida si aan u qiimeyno haddii ay yihiin musharaxa wanaagsan ee daaweynta CAR T-Cell." Haddii ay buuxiyaan dhammaan shuruudaha, waxaanu u soo saari doonaa T-unugyada si gaar ah bukaankaas.

"Taasi waa sababta aan u aaminsanahay inay muhiim tahay in laga dhigo mid aad u qiimo badan." Waxaan xakameyn karnaa qiimaha si ka yara wanaagsan annagoo ku rakibaya shaybaarkeena, ayuu yidhi.

Sasha Cumar ayaa sheegtay in shaybaadhka cusub ee shirkaddu uu shaqayn doono dhamaadka bisha March ee sanadkan, isla markaana ay hawluhu dib u bilaaban doonaan sida ugu dhakhsaha badan si loo daboolo baahida daawaynta.

Aagga cusub ee 12,000 sq ft wuxuu noqon doonaa Kota Damansara, iyada oo shaybaarku uu qaadan doono qiyaastii 7,000 sq ft oo bannaan ah iyo qaab dhismeedka xafiisku wuxuu qaadanayaa booska haray.

Daawooyinka dhawaan la sameeyay, sida CAR-T (chimeric antigen reseptor T-cell), waa dawooyin nolosha beddela oo loogu talagalay dadka daalay ikhtiyaarkooda daawaynta ee suurtogalka ah. Daawayntan goynta ah waxaa lagu bixiyaa habab aan dhaqameed ahayn, oo ay ku jiraan hawlo taxane ah oo dheer, adag oo si heer sare ah loo agaasimay gudaha xarumaha bixiyaha daryeelka caafimaadka. Bixiyeyaasha ayaa siyaalo kala duwan uga faa'iidaysan doona daawayntan, laga bilaabo sare u qaadida sumcadooda urur-goynta ilaa ay bixiyaan barnaamijyo faa'iido-abuur leh. Si kastaba ha ahaatee, keenista daawayntan horumarsan ee ugu danbaysay waxay keenaysaa caqabado dhaqaale iyo hawleed oo wayn hadii aan si taxadar leh loo qiimayn oo aan loo diyaar garoobin.

Waa maxay daaweynta CAR T-Cell (Chimeric antigen receptors)?

CAR T-Cell therapy waa nooc ka mid ah tallaalka difaaca jirka ee isticmaala unugyada T-ga ee sida gaarka ah wax looga beddelay kuwaas oo qayb ka ah habdhiskeenna difaaca la dagaallanka kansarka. A sample of patients T cells are collected from the blood, then it is modified to produce special structures called chimeric antigen receptors (CAR) on their surface. When these modified CAR cells are reinfused in the patient, these new cells attack the specific antigen and kill the buro unugyada.

Sidee ayuu u shaqeeyaa CAR T-Cell therapy?

CAR T-cell therapy takes help from body’s own immune system to attack and kill cancer cells. This is done by removing some specified cells from the blood of the patient, modifying them in the lab and re-injecting them into the patient. CAR T-cell therapy has produced very encouraging results in Liin-dhiska non-Hodgkin and thus approved by FDA.

Musharixiinta saxda ah ee daaweynta CAR T-cell 

At present FDA has approved CAR T-Cell therapy for some forms of aggressive and refractory Non-Hodgkin lymphoma, Myeloma oo soo noqnoqonaysa oo dib u celinaysa Lymphoblastic lymphoblastic leukemia. Bukaanku wuxuu u baahan yahay inuu soo diro warbixinno caafimaad oo buuxa si uu u hubiyo isticmaalka daawaynta CAR T-Cell ee daawaynta.

Shuruudaha ka mid noqoshada CAR T-cell therapy:

1. Bukaanka qaba CD19 + B-cell Lymphoma (Uguyaraan 2 isku darka hore chemotherapy nidaam)

2. Inaad gaarto 3 ilaa 75 sano

3. Dhibcaha ECOG ≤2

4. Haweenka leh awoodda dhalmo waa inay yeeshaan kaadi uurka baaritaanka la qaaday oo la caddeeyey inuu yahay mid taban daaweynta ka hor. Dhamaan bukaanada waxay isku raaceen inay isticmaalaan habab lagu kalsoonaan karo ee ka hortaga uurka inta lagu jiro mudada tijaabada iyo ilaa dabagal lagu sameeyo waqtiga ugu dambeeya.

Shuruudaha ka-saarista ee daaweynta CAR T-cell:

1. Dhiig-kar gudaha ah ama miyir-beel

2. Neefsashada oo xumaata

3. Xinjirowga xididdada dhiigga ku faafa

4. Hematosepsis ama Infekshan firfircoon oo aan la xakamayn

5. Xakamayn la'aan macaanka

Faa'iidooyinka daaweynta CAR T-Cell

1. > 5000 kiisaska CAR T oo ay sameeyeen dhakhaatiir xirfad sare leh.
2. Isbitaalada Shiinaha waxay soo saareen noocyo badan oo CAR T Cell ah oo ay kujiraan CD19 & CD 22 kadibna wadan kale oo aduunka ah.
3. Shiinaha wuxuu ku socdaa in kabadan 300 tijaabooyin caafimaad oo ku saabsan daaweynta CAR T Cell. In ka badan waddammada kale ee meeraha ka jira.
4. Saamaynta caafimaad ee CAR T Cell waxay la mid tahay ta USA ama waddan kale oo mararka qaarkood way ka fiicantahay.

Nidaamka daaweynta ee daaweynta CAR T-Cell

• Qiimeyn dhameystiran ee bukaanka
• Ururinta unugyada jirka
• T-unugyada ayaa markaa lagu farsameeyaa shaybaarka
• T-Unugyada hida-wadaha ayaa markaa lagu dhuftaa iyadoo la adeegsanayo iyaga oo ku koraya shaybaarka. Unugyadan waa la qaboojiyey ka dibna waxaa loo diraa xarumaha daaweynta.
• Buugga kahor, bukaanka waxaa lasiin karaa kiimiko ku daaweynta kansarkooda. Tani waxay ka caawineysaa daaweynta inay u shaqeyso si ka wanaagsan.
• Waxyar kadib daaweynta kemotherabi CAR T-Unugyada waxaa lagu shubaa nidaam u eg faleebada dhiigga.
• Bukaanka waxaa u jira 2-3 bilood oo soo kabasho ah.

Waqtiga daaweynta CAR T-Cell

1. Imtixaan & imtixaan: hal toddobaad

2. Daaweynta ka hor & T-Cell Ururinta: hal toddobaad

3. T-cell diyaarinta & soo noqoshada: laba-saddex toddobaad

4. Falanqaynta Waxtarka 1aad: saddex toddobaad

5. Falanqaynta Waxtarka 2aad: saddex toddobaad

Qiimaha daawaynta CAR T-cell ee Malaysia

Qiimaha daawaynta CAR T-Cell ee Malaysiya waxay noqon doontaa qiyaastii inta u dhaxaysa $ 45000 - 50,000 USD. Faahfaahinta shuruudaha u-qalmitaanka iyo qiyaasta kharashka fadlan u soo dir warbixinnadaada caafimaad info@cancerfax.com magacaaga iyo da'daada sida mawduuca.

Sidoo kale akhri sidan: Daaweynta CAR T Cell ee Hindiya 

Dhibaatooyinka ay keento CAR T-Cell therapy

Saameynaha guud ee CAR T-cell therapy waxaa ka mid ah:

• Calaamadaha sii deynta Cytokine
  Xaaladaha qaarkood, bukaanku waxaa ku dhici kara astaamo u eg hargabka sida qandho, dhaxan, madax xanuun, lallabbo, matag, saxaro dabacsan, iyo murqaha ama kalagoysyada oo xanuuna. Waxay kaloo sababi kartaa cadaadis dhiig oo hooseeya, neefsashada oo dhib ah, iyo garaaca wadnaha oo dhakhso ah. Dhibaatooyinkan soo raaca waxay u sabab yihiin sii deynta cytokines ee unugyada difaaca jirka inta lagu jiro daaweynta CAR T-cell. Calaamadahaasi badanaa waa kuwa fudud, laakiin waxay halis ku noqon karaan oo nolosha qaar khatar ku ah bukaannada qaarkood.
• Dhacdooyinka neerfaha
  Dhacdooyinka neerfaha ayaa dhici kara waxayna ku noqon karaan bukaanada qaarkood qatar. Dhacdooyinka noocan oo kale ah waxaa ka mid ah maskaxda maskaxda (cillad maskaxeed iyo cillad), jahwareer, hadalka oo adkaada, kacsiga, suuxdinta, lulmo, xaalad miyir doorsoon iyo isu dheelitirnaan la'aan.
• Neutropaenia iyo Dhiigyaraan
  Bukaanjiifka qaar ayaa laga yaabaa inay ku dhacdo neutropenia ama unugyada cad cad oo hooseeya.  Sidoo kale, dhiig yari ama unugyada dhiigga cas oo hooseeya ayaa waliba dhici kara daaweyntan awgeed.
  Nasiib wanaagse, inta badan waxyeelooyinkan sida caadiga ah kaligood ayaa lagu xaliyaa ama lagu maamuli karaa isticmaalka  daawooyinka.

Sidee waxtar u leedahay daaweynta CAR T-Cell?

CAR T-cell therapy for the treatment of qanjiro and other blood cancers has shown promising outcomes. Since CAR T-cell treatment, many patients who had previously relapsed blood tumours had promising results and no evidence of cancer. It has also aided in the rehabilitation of patients who have previously failed to respond to most traditional cancer therapies.

Si kastaba ha noqotee, daraasadaha muddada-dheer ee loogu talagalay bukaanka ballaaran ee bukaanka ah ayaa loo baahan yahay si loo xaqiijiyo waxtarka daaweyntan. Tijaabooyin ballaaran ayaa sidoo kale gacan ka geysan doona go'aaminta suurtagalnimada dhibaatooyinka soo raaca iyo dariiqooyinka saxda ah ee lagula macaamilo.

Isbitaalo bixiya daawaynta CAR T-cell ee Malaysia

• Xarunta Caafimaadka ee Sunway, Selangor
• Isbitaalka Columbia Asia, Kuala Lumpur

Sideen ku daweyn karaa Malaysia?

Bukaanku wuu wici karaa + 91 96 1588 1588 ama emayl ku soo dir kansarfax@gmail.com oo leh tafaasiisha bukaanka iyo warbixinada caafimaadka waxaanu diyaarin doonaa ra'yi labaad, qorshe daaweyn iyo qiyaasta kharashyada.